



Clinical trial results:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Summary

EudraCT number	2019-002932-10
Trial protocol	LT ES PL EE FR LV
Global end of trial date	03 May 2022

Results information

Result version number	v3 (current)
This version publication date	15 December 2022
First version publication date	06 July 2022
Version creation reason	• New data added to full data set LPV Results

Trial information

Trial identification

Sponsor protocol code	J2T-DM-KGAB, DRM06-AD04
-----------------------	-------------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04146363
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 17801

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-285-4559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 May 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	03 May 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 September 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Estonia: 8
Country: Number of subjects enrolled	France: 7
Country: Number of subjects enrolled	Latvia: 11
Country: Number of subjects enrolled	Lithuania: 18
Country: Number of subjects enrolled	Poland: 81
Country: Number of subjects enrolled	Australia: 39
Country: Number of subjects enrolled	Canada: 23
Country: Number of subjects enrolled	Korea, Republic of: 34
Country: Number of subjects enrolled	United States: 190
Country: Number of subjects enrolled	Spain: 13
Worldwide total number of subjects	424
EEA total number of subjects	138

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	55
Adults (18-64 years)	338
From 65 to 84 years	29
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

Participants who did not achieve an Investigator Global Assessment (IGA) of 0 or 1 or EASI-75 at Week 16 and those participants who did not maintain an Eczema Area Severity Index (EASI)-50 response following re-randomization at Weeks 24, 32, 40, or 48 were assigned to an Escape Arm and received 250 mg Lebrikizumab as open-label Q2W through Week 52.

Pre-assignment

Screening details:

Participants who did not achieve an EASI-50 response after 8 weeks in the Escape Arm were terminated from the study.

Period 1

Period 1 title	Induction Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Induction - Placebo (PBO)

Arm description:

Induction Period (Baseline-Week 16): Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.

Arm title	Induction - Lebrikizumab (Leb) Q2W
------------------	------------------------------------

Arm description:

Induction Period (Baseline-Week 16): 500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.

Arm type	Experimental
Investigational medicinal product name	Lebrikizumab
Investigational medicinal product code	LY3650150
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.

Number of subjects in period 1	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W
Started	141	283
Received at Least One Dose of Study Drug	141	282
Completed	120	263
Not completed	21	20
Positive quantiferon test	-	1
Adverse event, non-fatal	1	2
Due to Epidemic/Pandemic	1	2
Withdrawal by Subject	6	3
Lost to follow-up	1	4
Lack of efficacy	7	2
Protocol deviation	5	6

Period 2

Period 2 title	Maintenance Blinded Treatment Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Maintenance – Placebo Responder/Placebo

Arm description:

Maintenance Secondary Population: Maintenance Period (Week 16 to Week 52):
One SC injection of Placebo Q2W until Week 50.

Two placebo SC injections as loading dose on Week 16 and Week 18.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One SC injection of Placebo Q2W.

Arm title	Maintenance - PBO Responder/Lebrikizumab 250 Q4W
------------------	--

Arm description:

Maintenance Secondary Population: Maintenance Period (Week 16-Week 52):

One 250 mg Lebrikizumab SC injection every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.

One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.

For participants who received placebo in the Induction Period, the maintenance loading dose is:

Two 250 mg Lebrikizumab SC injections on Week 16.

Two placebo injections on Week 18.

Arm type	Experimental
Investigational medicinal product name	Lebrikizumab
Investigational medicinal product code	LY3650150
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and two placebo SC injections on Week 18.

One 250 mg Lebrikizumab SC injection Every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.

One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.

Arm title	Maintenance – PBO Responder/Lebrikizumab 250 Q2W
------------------	--

Arm description:

Maintenance Secondary Population: Maintenance Period (Week 16-Week 52):

One 250 mg Lebrikizumab SC injection Q2W until Week 50.

For participants who received placebo in the Induction Period, the maintenance loading dose is:

Two 250 mg Lebrikizumab SC injections on Week 16.

Two 250 mg Lebrikizumab SC injections on Week 18.

Arm type	Experimental
Investigational medicinal product name	Lebrikizumab
Investigational medicinal product code	LY3650150
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

250 mg Lebrikizumab SC injection Q2W.

Arm title	Maintenance - Lebrikizumab Responder/Placebo
------------------	--

Arm description:

Maintenance Primary Population:

Maintenance Primary Population: Maintenance Period (Week 16 to Week 52): One SC injection of Placebo Q2W until Week 50.

Two placebo SC injections as loading dose on Week 16 and Week 18.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One SC injection of Placebo Q2W.

Arm title	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W
------------------	---

Arm description:

Maintenance Period (Week 16-Week 52):

One 250 mg Lebrikizumab SC injection every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.

One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.

To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:

One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.

Two placebo injections on Week 18

Arm type	Experimental
Investigational medicinal product name	Lebrikizumab
Investigational medicinal product code	LY3650510
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and two placebo SC injections on Week 18.

One 250 mg Lebrikizumab SC injection Every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.

One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.

Arm title	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
------------------	---

Arm description:

Maintenance Primary Population: Maintenance Period (Week 16-Week 52):

One 250 mg Lebrikizumab SC injection Q2W until Week 50.

To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:

One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.

One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.

Arm type	Experimental
Investigational medicinal product name	Lebrikizumab
Investigational medicinal product code	LY3650510
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

250 mg Lebrikizumab SC injection Q2W.

Number of subjects in period 2^[1]	Maintenance – Placebo Responder/Placebo	Maintenance - PBO Responder/Lebrikizu mab 250 Q4W	Maintenance – PBO Responder/Lebrikizu mab 250 Q2W
Started	4	10	10
Completed	2	10	9
Not completed	2	0	1
Physician decision	1	-	-
Adverse event, non-fatal	-	-	-
Withdrawal by Subject	-	-	1
Entered Escape Arm	1	-	-
Lost to follow-up	-	-	-

Lack of efficacy	-	-	-
------------------	---	---	---

Number of subjects in period 2 ^[1]	Maintenance - Lebrikizumab Responder/Placebo	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Started	32	63	62
Completed	22	54	48
Not completed	10	9	14
Physician decision	1	-	-
Adverse event, non-fatal	-	1	1
Withdrawal by Subject	2	3	5
Entered Escape Arm	7	4	6
Lost to follow-up	-	1	1
Lack of efficacy	-	-	1

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Participants who responded to treatment, defined as and IGA of 0 or 1 or a 75% reduction in EASI from baseline to Week 16, entered the Maintenance Period and re-randomized to the following treatment groups: lebrikizumab 250 mg Q2W, lebrikizumab 250 mg Q4W, or placebo Q2W.

Period 3

Period 3 title	Maintenance Open Label (OL) Escape Arm
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	Escape Arm Week 16 - Maintenance OL - PBO NR/Leb 250 Q2W

Arm description:

Maintenance Escape Period (Week 16 to Week 52):

Blinded loading doses based on prior treatment assignment will be administered, followed by one 250 mg Lebrikizumab SC injection Q2W until Week 50 in an open-label fashion.

For participants who received placebo in the Induction Period, the loading dose is:

Two 250 mg Lebrikizumab SC injection on Week 16.

Two 250 mg Lebrikizumab SC injections on Week 18.

For participants who do not maintain an acceptable response during the Maintenance Period and entered the Escape Arm, the loading doses will be administrated at entry and 2 weeks after entry based on the treatment assignment prior to entering escape arm.

Participants who did not achieve an EASI-50 response after 8 weeks in the Escape Arm were terminated from the study.

Arm type	Experimental
Investigational medicinal product name	Lebrikizumab
Investigational medicinal product code	LY3650510
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

250 mg Lebrikizumab Q2W.

Arm title	Escape Arm Week 16 - Maintenance OL - Leb NR/Leb 250 Q2W
------------------	--

Arm description:

Maintenance Escape Period (Week 16 to Week 52):

Blinded loading doses based on prior treatment assignment will be administered, followed by one 250 mg Lebrikizumab SC injection Q2W until Week 50 in an open-label fashion.

To maintain the loading dose blind, for participants who received Lebrikizumab in the Induction Period, the loading dose is:

One 250 mg Lebrikizumab SC injection and one placebo on Week 16.

One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.

For participants who do not maintain an acceptable response during the Maintenance Period and entered the Escape Arm, the loading doses will be administered at entry and 2 weeks after entry based on the treatment assignment prior to entering escape arm.

Participants who did not achieve an EASI-50 response after 8 weeks in the Escape Arm were terminated from the study.

Arm type	Experimental
Investigational medicinal product name	Lebrikizumab
Investigational medicinal product code	LY3650510
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Maintenance Escape Period (Week 16 to Week 52): 250 mg Lebrikizumab SC injection Q2W.

Arm title	Escape Arm Week 24 - 48 - Maintenance OL - Leb 250 Q2W
------------------	--

Arm description:

Maintenance Escape Period (Week 24 to Week 48): One 250 mg Lebrikizumab SC injection Q2W.

Arm type	Experimental
Investigational medicinal product name	Lebrikizumab
Investigational medicinal product code	LY3650510
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Maintenance Escape Period (Week 24 to Week 48): 250 mg Lebrikizumab Q2W.

Number of subjects in period 3	Escape Arm Week 16 - Maintenance OL - PBO NR/Leb 250 Q2W	Escape Arm Week 16 - Maintenance OL - Leb NR/Leb 250 Q2W	Escape Arm Week 24 - 48 - Maintenance OL - Leb 250 Q2W
Started	96	106	18
Completed	77	77	15
Not completed	19	29	3
Physician decision	1	1	-
Adverse event, non-fatal	1	4	-

Pregnancy	-	1	-
Withdrawal by Subject	5	2	2
Lost to follow-up	1	2	-
EASI Scoring Error	-	2	-
Lack of efficacy	11	17	1

Baseline characteristics

Reporting groups

Reporting group title	Induction - Placebo (PBO)
-----------------------	---------------------------

Reporting group description:

Induction Period (Baseline-Week 16): Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.

Reporting group title	Induction - Lebrikizumab (Leb) Q2W
-----------------------	------------------------------------

Reporting group description:

Induction Period (Baseline-Week 16):

500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.

Reporting group values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W	Total
Number of subjects	141	283	424
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	18	37	55
Adults (18-64 years)	113	225	338
From 65-84 years	10	19	29
85 years and over	0	2	2
Gender categorical			
Units: Subjects			
Female	73	141	214
Male	68	142	210
Race			
Units: Subjects			
American Indian or Alaska Native	0	7	7
Asian	31	39	70
Native Hawaiian or Other Pacific Islander	0	2	2
Black or African American	16	33	49
White	93	196	289
More than one race	1	4	5
Unknown or Not Reported	0	2	2
Region of Enrollment			
Units: Subjects			
Canada	7	16	23
South Korea	13	21	34
Latvia	6	5	11
United States	62	128	190
Poland	25	56	81

Australia	13	26	39
France	0	7	7
Lithuania	7	11	18
Spain	4	9	13
Estonia	4	4	8

End points

End points reporting groups

Reporting group title	Induction - Placebo (PBO)
-----------------------	---------------------------

Reporting group description:

Induction Period (Baseline-Week 16): Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.

Reporting group title	Induction - Lebrikizumab (Leb) Q2W
-----------------------	------------------------------------

Reporting group description:

Induction Period (Baseline-Week 16):

500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.

Reporting group title	Maintenance – Placebo Responder/Placebo
-----------------------	---

Reporting group description:

Maintenance Secondary Population: Maintenance Period (Week 16 to Week 52):
One SC injection of Placebo Q2W until Week 50.

Two placebo SC injections as loading dose on Week 16 and Week 18.

Reporting group title	Maintenance - PBO Responder/Lebrikizumab 250 Q4W
-----------------------	--

Reporting group description:

Maintenance Secondary Population: Maintenance Period (Week 16-Week 52):

One 250 mg Lebrikizumab SC injection every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.

One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.

For participants who received placebo in the Induction Period, the maintenance loading dose is:

Two 250 mg Lebrikizumab SC injections on Week 16.

Two placebo injections on Week 18.

Reporting group title	Maintenance – PBO Responder/Lebrikizumab 250 Q2W
-----------------------	--

Reporting group description:

Maintenance Secondary Population: Maintenance Period (Week 16-Week 52):

One 250 mg Lebrikizumab SC injection Q2W until Week 50.

For participants who received placebo in the Induction Period, the maintenance loading dose is:

Two 250 mg Lebrikizumab SC injections on Week 16.

Two 250 mg Lebrikizumab SC injections on Week 18.

Reporting group title	Maintenance - Lebrikizumab Responder/Placebo
-----------------------	--

Reporting group description:

Maintenance Primary Population:

Maintenance Primary Population: Maintenance Period (Week 16 to Week 52): One SC injection of Placebo Q2W until Week 50.

Two placebo SC injections as loading dose on Week 16 and Week 18.

Reporting group title	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W
-----------------------	---

Reporting group description:

Maintenance Period (Week 16-Week 52):

One 250 mg Lebrikizumab SC injection every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.

One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.

To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:

One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.

Two placebo injections on Week 18

Reporting group title	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
-----------------------	---

Reporting group description:

Maintenance Primary Population: Maintenance Period (Week 16-Week 52):

One 250 mg Lebrikizumab SC injection Q2W until Week 50.

To maintain the blind, for participants who received Lebrikizumab in the Induction Period, the maintenance loading dose is:

One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 16.

One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.

Reporting group title	Escape Arm Week 16 - Maintenance OL - PBO NR/Leb 250 Q2W
-----------------------	--

Reporting group description:

Maintenance Escape Period (Week 16 to Week 52):

Blinded loading doses based on prior treatment assignment will be administered, followed by one 250 mg Lebrikizumab SC injection Q2W until Week 50 in an open-label fashion.

For participants who received placebo in the Induction Period, the loading dose is:

Two 250 mg Lebrikizumab SC injection on Week 16.

Two 250 mg Lebrikizumab SC injections on Week 18.

For participants who do not maintain an acceptable response during the Maintenance Period and entered the Escape Arm, the loading doses will be administrated at entry and 2 weeks after entry based on the treatment assignment prior to entering escape arm.

Participants who did not achieve an EASI-50 response after 8 weeks in the Escape Arm were terminated from the study.

Reporting group title	Escape Arm Week 16 - Maintenance OL - Leb NR/Leb 250 Q2W
-----------------------	--

Reporting group description:

Maintenance Escape Period (Week 16 to Week 52):

Blinded loading doses based on prior treatment assignment will be administered, followed by one 250 mg Lebrikizumab SC injection Q2W until Week 50 in an open-label fashion.

To maintain the loading dose blind, for participants who received Lebrikizumab in the Induction Period, the loading dose is:

One 250 mg Lebrikizumab SC injection and one placebo on Week16.

One 250 mg Lebrikizumab SC injection and one placebo SC injection on Week 18.

For participants who do not maintain an acceptable response during the Maintenance Period and entered the Escape Arm, the loading doses will be administrated at entry and 2 weeks after entry based on the treatment assignment prior to entering escape arm.

Participants who did not achieve an EASI-50 response after 8 weeks in the Escape Arm were terminated from the study.

Reporting group title	Escape Arm Week 24 - 48 - Maintenance OL - Leb 250 Q2W
-----------------------	--

Reporting group description:

Maintenance Escape Period (Week 24 to Week 48): One 250 mg Lebrikizumab SC injection Q2W.

Subject analysis set title	Escape Arm Week 24 - 48 - Maintenance OL - Leb 250 Q2W
----------------------------	--

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Escape Arm data included any participants from Induction Period entering the Escape Arm at W16 and participants in the Maintenance Period coming from Maintenance 250 mg Q2W dosing.

Primary: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥ 2 Points From Baseline to Week 16

End point title	Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥ 2 Points From Baseline to Week 16
-----------------	--

End point description:

The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Analysis Population Description (APD): All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. Markov Chain Monte Carlo Multiple Imputation (MCMC-MI) was used to handle missing data.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to Week 16

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	283		
Units: Percentage of Participants				
number (confidence interval 95%)	12.8 (7.0 to 18.6)	43.0 (37.1 to 49.0)		

Statistical analyses

Statistical analysis title	IGA Baseline to Week 16
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	424
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	29.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	21.4
upper limit	37.8

Primary: Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) ($\geq 75\%$ Reduction in EASI Score) From Baseline to Week 16

End point title	Percentage of Participants Achieving Eczema Area And Severity
-----------------	---

End point description:

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).

The EASI-75 responder is defined as a participant who achieves a $\geq 75\%$ improvement from baseline in the EASI score.

APD: All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Primary
End point timeframe:	
Baseline to Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	283		
Units: Percentage of Participants				
number (confidence interval 95%)	16.4 (9.8 to 23.0)	59.3 (53.4 to 65.2)		

Statistical analyses

Statistical analysis title	EASI-75
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	424
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	42.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.5
upper limit	51

Secondary: Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥ 2 Points From Baseline to Week 2

End point title	Percentage of Participants With an IGA Score of 0 or 1 and a
-----------------	--

End point description:

he IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

APD: All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 2

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	283		
Units: Percentage of Participants				
number (confidence interval 95%)	0.7 (0.0 to 2.1)	2.5 (0.7 to 4.4)		

Statistical analyses

Statistical analysis title	IGA Baseline to Week 2
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	424
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.218644
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	4

Secondary: Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥ 2 Points From Baseline to Week 4

End point title	Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥ 2 Points From Baseline to Week 4
-----------------	--

End point description:

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and

lichenification.

APD: All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
End point timeframe:	
Baseline to Week 4	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	283		
Units: Percentage of Participants				
number (confidence interval 95%)	0.8 (-0.7 to 2.3)	10.6 (6.9 to 14.2)		

Statistical analyses

Statistical analysis title	IGA Baseline to Week 4
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	424
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.000982
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	9.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.7
upper limit	13.6

Secondary: Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥ 2 Points From Baseline to Week 16 in Adults

End point title	Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥ 2 Points From Baseline to Week 16 in Adults
-----------------	---

End point description:

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

APD: All randomized, adult participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
End point timeframe:	
Baseline to Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	123	246		
Units: Percentage of Participants				
number (confidence interval 95%)	11.3 (5.4 to 17.2)	42.2 (35.8 to 48.6)		

Statistical analyses

Statistical analysis title	IGA - Adults Baseline to Week 16
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	369
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	30.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	22.1
upper limit	39.4

Secondary: Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 16

End point title	Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 16
End point description:	<p>The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).</p> <p>The EASI-90responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the EASI score.</p> <p>APD: All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.</p>
End point type	Secondary

End point timeframe:

Baseline to Week 16

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	283		
Units: Percentage of Participants				
number (confidence interval 95%)	9.0 (3.9 to 14.0)	38.3 (32.5 to 44.1)		

Statistical analyses

Statistical analysis title	EASI-90
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	424
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	28.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	21.3
upper limit	36.3

Secondary: Percent Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16

End point title	Percent Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
-----------------	--

End point description:

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." Least Squares (LS) Mean was calculated using analysis of covariance (ANCOVA) model with treatment and randomization strata (region, disease severity, age) as fixed factors and baseline value as covariate.

APD: All randomized participants, with a Baseline Pruritus NRS score >0, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	276		
Units: Percent Change				
least squares mean (standard error)	-15.06 (\pm 3.833)	-45.48 (\pm 3.143)		

Statistical analyses

Statistical analysis title	Pruritus Numerical Rating Scale (NRS)
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	412
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-30.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-38.1
upper limit	-22.7
Variability estimate	Standard error of the mean
Dispersion value	3.915

Secondary: Percentage of Participants With a Pruritus NRS Score of ≥ 4 -points at Baseline Who Achieve a ≥ 4 -point Reduction in Pruritus NRS Score From Baseline to Week 16

End point title	Percentage of Participants With a Pruritus NRS Score of ≥ 4 -points at Baseline Who Achieve a ≥ 4 -point Reduction in Pruritus NRS Score From Baseline to Week 16
-----------------	---

End point description:

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

APD: All randomized participants, with a Baseline Pruritus NRS score ≥ 4 , even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
End point timeframe:	
Baseline to Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	130	263		
Units: Percentage of Participants				
number (confidence interval 95%)	13.0 (7.0 to 18.9)	45.9 (39.8 to 52.1)		

Statistical analyses

Statistical analysis title	Pruritus NRS Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	32.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	24.6
upper limit	41.3

Secondary: Percentage of Participants With a Pruritus NRS Score of ≥ 5 -points at Baseline Who Achieve a ≥ 4 -point Reduction in Pruritus NRS Score From Baseline to Week 16

End point title	Percentage of Participants With a Pruritus NRS Score of ≥ 5 -points at Baseline Who Achieve a ≥ 4 -point Reduction in Pruritus NRS Score From Baseline to Week 16
End point description:	Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
APD:	All randomized participants, with Baseline Pruritus NRS score ≥ 5 , even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.
End point type	Secondary
End point timeframe:	
Baseline to Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	123	141		
Units: Percentage of Participants				
number (confidence interval 95%)	13.7 (7.5 to 20.0)	49.0 (42.7 to 55.4)		

Statistical analyses

Statistical analysis title	Pruritus NRS Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	264
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	35.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	26.3
upper limit	43.9

Secondary: Percent Change in EASI Score From Baseline to Week 16

End point title	Percent Change in EASI Score From Baseline to Week 16
End point description:	
<p>The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). LS Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 16	
<p>APD: All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.</p>	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	283		
Units: Percent Change				
least squares mean (standard error)	-26.01 (\pm 4.031)	-64.31 (\pm 3.156)		

Statistical analyses

Statistical analysis title	Percent Change in EASI Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	424
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-38.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-46.4
upper limit	-30.2
Variability estimate	Standard error of the mean
Dispersion value	4.151

Secondary: Change From Baseline in Percent Body Surface Area (BSA) at Week 16

End point title	Change From Baseline in Percent Body Surface Area (BSA) at Week 16
End point description:	
<p>The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region * % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD.</p> <p>MMRM was used to handle all missing data.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 16	
APD: All randomized participants, with observed BSA data, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	77	236		
Units: percentage of body surface area				
least squares mean (standard error)	-11.77 (\pm 1.86)	-30.2 (\pm 1.31)		

Statistical analyses

Statistical analysis title	BSA
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	313
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Mixed models analysis
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-18.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.4
upper limit	-14.5
Variability estimate	Standard error of the mean
Dispersion value	2

Secondary: Percentage of Participants Achieving EASI-90 From Baseline to Week 4

End point title	Percentage of Participants Achieving EASI-90 From Baseline to Week 4
-----------------	--

End point description:

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).

The EASI-90 responder is defined as a participant who achieves a \geq 90% improvement from baseline in the EASI score.

APD: All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 4

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	283		
Units: Percentage of Participants				
number (confidence interval 95%)	1.6 (-0.6 to 3.8)	12.4 (8.5 to 16.3)		

Statistical analyses

Statistical analysis title	EASI-90
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	424
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.000878
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	10.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.2
upper limit	15.2

Secondary: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

End point title	Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
-----------------	--

End point description:

The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

LS Mean was calculated using the ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

APD: All randomized participants, with non-missing baseline DLQI score, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	121 ^[1]	239 ^[2]		
Units: Score on a Scale				
least squares mean (standard error)	-2.9 (± 1.1)	-8.7 (± 1.05)		

Notes:

[1] - MCMC-MI was used to handle missing data.

[2] - MCMC-MI was used to handle missing data.

Statistical analyses

Statistical analysis title	DLQI
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	360
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.1
upper limit	-4.5
Variability estimate	Standard error of the mean
Dispersion value	0.68

Secondary: Percentage of Participants Achieving ≥4 Point Improvement in DLQI From Baseline to Week 16

End point title	Percentage of Participants Achieving ≥4 Point Improvement in DLQI From Baseline to Week 16
-----------------	--

End point description:

The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

MCMC-MI was used to handle all missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 16

APD: All randomized participants, with non-missing baseline DLQI score, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	121 ^[3]	239 ^[4]		
Units: Percentage of Participants				
number (confidence interval 95%)	32.4 (23.8 to 41.1)	71.45 (65.7 to 77.4)		

Notes:

[3] - MCMC-MI was used to handle missing data.

[4] - MCMC-MI was used to handle missing data.

Statistical analyses

Statistical analysis title	DLQI
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	360
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	38.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	28.3
upper limit	49.3

Secondary: Percentage of Participants With a DLQI Total Score of ≥ 4 -point at Baseline Achieving ≥ 4 -point Improvement in DLQI From Baseline to Week 16

End point title	Percentage of Participants With a DLQI Total Score of ≥ 4 -point at Baseline Achieving ≥ 4 -point Improvement in DLQI From Baseline to Week 16
-----------------	--

End point description:

The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

MCMC-MI was used to handle missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 16

APD: All randomized participants, with a DLQI Total Score of ≥ 4 -point at baseline, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	116	226		
Units: Percentage of Participants				
number (confidence interval 95%)	33.8 (24.9 to 42.8)	75.6 (69.9 to 81.4)		

Statistical analyses

Statistical analysis title	DLQI ≥ 4 -point at Baseline
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	342
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	41.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	31.2
upper limit	52.3

Secondary: Percent Change in Sleep-loss Score From Baseline to Week 16

End point title	Percent Change in Sleep-loss Score From Baseline to Week 16
End point description:	
<p>Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale [0 (not at all) to 4 (unable to sleep at all)]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.</p> <p>APD: All randomized participants, with baseline sleep-loss score > 0, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	132	269		
Units: Percent Change				
least squares mean (standard error)	-15.99 (\pm 5.139)	-48.33 (\pm 4.175)		

Statistical analyses

Statistical analysis title	Sleep-loss Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	401
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-32.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-42.6
upper limit	-22.1
Variability estimate	Standard error of the mean
Dispersion value	5.23

Secondary: Change From Baseline in Sleep-loss Score at Week 16

End point title	Change From Baseline in Sleep-loss Score at Week 16
End point description:	<p>Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale [0 (not at all) to 4 (unable to sleep at all)]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors.</p> <p>APD: All randomized participants, non-missing baseline Sleep-loss score, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.</p>
End point type	Secondary
End point timeframe:	
Baseline, Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	276		
Units: Score on a Scale				
least squares mean (standard error)	-0.38 (\pm 0.096)	-1.13 (\pm 0.078)		

Statistical analyses

Statistical analysis title	Sleep-loss Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	412
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	-0.6
Variability estimate	Standard error of the mean
Dispersion value	0.098

Secondary: Percentage of Participants With a Sleep-loss Score ≥ 2 Points at Baseline Who Achieve a ≥ 2 Points Reduction From Baseline at Week 16

End point title	Percentage of Participants With a Sleep-loss Score ≥ 2 Points at Baseline Who Achieve a ≥ 2 Points Reduction From Baseline at Week 16
-----------------	---

End point description:

Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale [0 (not at all) to 4 (unable to sleep at all)]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary.

APD: All randomized participants, with baseline sleep-loss score ≥ 2 Points, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
End point timeframe:	
Baseline to Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	91	195		
Units: Percentage of Participants				
number (confidence interval 95%)	4.7 (0.3 to 9.2)	39.0 (32.1 to 46.0)		

Statistical analyses

Statistical analysis title	Sleep-loss Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	286
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	34.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	26.2
upper limit	43

Secondary: Percentage of Participants With a Pruritus NRS Score of ≥ 4 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 1

End point title	Percentage of Participants With a Pruritus NRS Score of ≥ 4 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 1
End point description:	Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
	APD: All randomized participants, with a Pruritus NRS Score of ≥ 4 Points at Baseline, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.
End point type	Secondary
End point timeframe:	
Baseline to Week 1	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	130	263		
Units: Percentage of Participants				
number (confidence interval 95%)	0.8 (0.0 to 2.3)	2.3 (0.5 to 4.1)		

Statistical analyses

Statistical analysis title	Pruritus NRS Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.275529
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	3.9

Secondary: Percentage of Participants With a Pruritus NRS Score of ≥ 4 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 2

End point title	Percentage of Participants With a Pruritus NRS Score of ≥ 4 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 2
-----------------	---

End point description:

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

APD: All randomized participant, with a Pruritus NRS Score of ≥ 4 Points at Baseline, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
End point timeframe:	
Baseline to Week 2	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	130	263		
Units: Percentage of Participants				
number (confidence interval 95%)	0.9 (-0.8 to 2.5)	6.1 (3.2 to 9.0)		

Statistical analyses

Statistical analysis title	Pruritus NRS Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.016656
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	5.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.9
upper limit	8

Secondary: Percentage of Participants With a Pruritus NRS Score of ≥ 4 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 4

End point title	Percentage of Participants With a Pruritus NRS Score of ≥ 4 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 4
-----------------	---

End point description:

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

APD: All randomized participants, with a Pruritus NRS Score of ≥ 4 Points at Baseline, if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 4

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	130	263		
Units: Percentage of Participants				
number (confidence interval 95%)	2.3 (0.0 to 4.9)	21.6 (16.5 to 26.5)		

Statistical analyses

Statistical analysis title	Pruritus NRS Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.000003
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	19.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.7
upper limit	25

Secondary: Percentage of Participants With a Pruritus NRS Score of ≥ 5 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 1

End point title	Percentage of Participants With a Pruritus NRS Score of ≥ 5 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 1
-----------------	---

End point description:

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

APD: All randomized participants, with a Pruritus NRS Score of ≥ 5 Points at Baseline, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 1

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	123	244		
Units: Percentage of Participants				
number (confidence interval 95%)	0.8 (0.0 to 2.4)	2.5 (0.5 to 4.4)		

Statistical analyses

Statistical analysis title	Pruritus NRS Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	367
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.244105
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	4.3

Secondary: Percentage of Participants With a Pruritus NRS Score of ≥ 5 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 2

End point title	Percentage of Participants With a Pruritus NRS Score of ≥ 5 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 2
End point description:	
Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."	
APD: All randomized participants, with a Pruritus NRS Score of ≥ 5 Points at Baseline, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.	
End point type	Secondary
End point timeframe:	
Baseline to Week 2	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	123	244		
Units: Percentage of Participants				
number (confidence interval 95%)	0.9 (-0.9 to 2.7)	6.6 (3.5 to 9.7)		

Statistical analyses

Statistical analysis title	Pruritus NRS Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	367
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.01445
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.2
upper limit	9.4

Secondary: Percentage of Participants With a Pruritus NRS Score of ≥ 5 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 4

End point title	Percentage of Participants With a Pruritus NRS Score of ≥ 5 Points at Baseline Who Achieve a ≥ 4 -point Reduction From Baseline to Week 4
-----------------	---

End point description:

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

APD: All randomized participants, with a Pruritus NRS Score of ≥ 5 Points at Baseline, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. MCMC-MI was used to handle missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 4

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	123	244		
Units: Percentage of Participants				
number (confidence interval 95%)	2.4 (0.0 to 5.2)	23.1 (17.8 to 28.5)		

Statistical analyses

Statistical analysis title	Pruritus NRS Score
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	367
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.000002
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	20.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	14.9
upper limit	26.9

Secondary: Percent Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16

End point title	Percent Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16
-----------------	---

End point description:

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), & subjective symptoms (C: 0-20) combine using $A/5 + 7*B/2 + C$ to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease.

LS Mean was calculated using the ANCOVA model with treatment group and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate. Missing Values were imputed using LOCF method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

APD: All randomized participants, with baseline SCORAD >0, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	138	276		
Units: Score on a Scale				
least squares mean (standard error)	-16.64 (\pm 3.162)	-46.93 (\pm 2.551)		

Statistical analyses

Statistical analysis title	SCORing Atopic Dermatitis
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	414
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-30.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-36.59
upper limit	-24
Variability estimate	Standard error of the mean
Dispersion value	3.203

Secondary: Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 16 - Health State Index

End point title	Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 16 - Health State Index
-----------------	---

End point description:

The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate. Missing Values were imputed using last observation carried forward (LOCF) method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

APD: All randomized participants, with non-missing EQ-5D-5L data at baseline, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	282		
Units: Score on a Scale				
least squares mean (standard error)				
Health State Index UK	0.0 (\pm 0.02)	0.2 (\pm 0.01)		
Health State Index US	0.0 (\pm 0.01)	0.1 (\pm 0.01)		

Statistical analyses

Statistical analysis title	Health State Index UK
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	423
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.1
upper limit	0.2
Variability estimate	Standard error of the mean
Dispersion value	0.02

Statistical analysis title	Health State Index US
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	423
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	0.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.08
upper limit	0.13
Variability estimate	Standard error of the mean
Dispersion value	0.013

Secondary: Change From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS)

End point title	Change From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS)
-----------------	---

End point description:

The EQ-5D-5L is a 2-part measurement. The second part is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

APD: All randomized participants, with non-missing EQ-5D-5L data at baseline, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. Missing values were imputed using LOCF method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	141	282		
Units: Score on a Scale				
least squares mean (standard error)	2.1 (± 1.64)	10.4 (± 1.33)		

Statistical analyses

Statistical analysis title	EQ-5D-5L VAS
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	423
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	8.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	5
upper limit	11.5
Variability estimate	Standard error of the mean
Dispersion value	1.66

Secondary: Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16

End point title	Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16
-----------------	---

End point description:

POEM is a 7-item, validated, questionnaire used by the participant to assess disease symptoms over the last week. The participant is asked to respond to 7 questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding and weeping. All 7 answers carry equal weight with a total possible score from 0 to 28 (answers scored as: No days=0; 1# 2 days = 1; 3-4 days = 2; 5#6 days = 3; everyday = 4). A high score is indicative of a poor quality of life. POEM responses will be captured using an electronic diary and transferred into the clinical database. LS Mean was calculated using MMRM model using treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit as covariates, geographic region, age group, baseline IGA (3 versus 4) score as fixed. MMRM was used to handle all missing data

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

APD: All randomized participants, with observed POEM data, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	70	203		
Units: Score on a Scale				
least squares mean (standard error)	-3.9 (± 0.72)	-11.3 (± 0.47)		

Statistical analyses

Statistical analysis title	POEM
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W

Number of subjects included in analysis	273
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.000001
Method	Mixed models analysis
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-7.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.9
upper limit	-5.7
Variability estimate	Standard error of the mean
Dispersion value	0.8

Secondary: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16 - Adolescents

End point title	Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16 - Adolescents
-----------------	--

End point description:

PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate. APD: All randomized, adolescent participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. Missing values were imputed using the LOCF method.

End point type	Secondary
End point timeframe:	
Baseline, Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	37		
Units: Score on a Scale				
least squares mean (standard error)	-2.80 (± 2.435)	-3.87 (± 1.830)		

Statistical analyses

Statistical analysis title	PROMIS Anxiety Adolescents
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	55
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.716224
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.93
upper limit	4.8
Variability estimate	Standard error of the mean
Dispersion value	2.917

Secondary: Change From Baseline in PROMIS Depression at Week 16 - Adolescent

End point title	Change From Baseline in PROMIS Depression at Week 16 - Adolescent
-----------------	---

End point description:

PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS depression has 8 questions on Emotion Distress-Depression (or Pediatric Depressive Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater depression. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

APD: All randomized, adolescent participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. Missing values were imputed using the LOCF method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	37		
Units: Score on a Scale				
least squares mean (standard error)	-0.11 (± 2.165)	-4.62 (± 1.623)		

Statistical analyses

Statistical analysis title	PROMIS Depression Adolescents
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	55
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.089275
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-4.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.73
upper limit	0.72
Variability estimate	Standard error of the mean
Dispersion value	2.599

Secondary: Change From Baseline in PROMIS Anxiety at Week 16 - Adults

End point title	Change From Baseline in PROMIS Anxiety at Week 16 - Adults
End point description:	<p>PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. The PROMIS measures will be completed by the participant in the study clinic. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate. APD: All randomized, adult participants, with Week 16 PROMIS anxiety data, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. Missing values are imputed with the LOCF method.</p>
End point type	Secondary
End point timeframe:	
Baseline, Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	244		
Units: Score on a Scale				
least squares mean (standard error)	-0.60 (± 0.660)	-3.91 (± 0.475)		

Statistical analyses

Statistical analysis title	PROMIS Anxiety Adults
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	366
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.000032
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-3.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.88
upper limit	-1.75
Variability estimate	Standard error of the mean
Dispersion value	0.796

Secondary: Change From Baseline in PROMIS Depression at Week 16 - Adults

End point title	Change From Baseline in PROMIS Depression at Week 16 - Adults
End point description:	
<p>PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. The PROMIS measures will be completed by the participant in the study clinic. PROMIS depression has 8 questions on Emotion Distress-Depression (or Pediatric Depressive Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater depression. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.</p> <p>APD: All randomized , adult participants, with Week 16 PROMIS Depression data, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. Missing values were imputed using the LOCF method.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 16	

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	122	244		
Units: Score on a Scale				
least squares mean (standard error)	-0.37 (± 0.579)	-3.07 (± 0.416)		

Statistical analyses

Statistical analysis title	PROMIS Depression Adults
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	366
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.000127
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.07
upper limit	-1.33
Variability estimate	Standard error of the mean
Dispersion value	0.697

Secondary: Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-Reported Comorbid Asthma

End point title	Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-Reported Comorbid Asthma
-----------------	--

End point description:

The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. The ACQ-5 score is the average of the individual item scores and ranges from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicate lower asthma control.

LS Mean was calculated using ANCOVA with treatment, geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate.

APD: All randomized participants, with non-missing baseline ACQ-5 score, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not f

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	95		
Units: Score on a Scale				
least squares mean (standard error)	-0.05 (± 0.117)	-0.14 (± 0.095)		

Statistical analyses

Statistical analysis title	Asthma Control Questionnaire
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	146
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.455291
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.33
upper limit	0.15
Variability estimate	Standard error of the mean
Dispersion value	0.121

Secondary: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16 - Adolescents

End point title	Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16 - Adolescents
-----------------	--

End point description:

The CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms & feelings, leisure, school or holidays, personal relationships, sleep, & treatment. The scoring of each question is: Very much = 3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses, and has a range of 0 to 30 (higher scores are indicative of greater impairment).

LS Mean was calculated using MMRM model which includes treatment, baseline value, visit, the interaction of the baseline value-by-visit as covariates, the interaction of treatment by-visit, geographic region, age group, and baseline IGA (3 versus 4) score as fixed factors.

MMRM was used to handle all missing data.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 16

APD: All randomized, adolescent participants, with non-missing baseline CDLQI score, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.

End point values	Induction - Placebo (PBO)	Induction - Lebrikizumab (Leb) Q2W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	26		
Units: Score on a Scale				
least squares mean (standard error)	-1.0 (± 1.29)	-8.0 (± 0.80)		

Statistical analyses

Statistical analysis title	Children's Dermatology Life Quality Index
Comparison groups	Induction - Placebo (PBO) v Induction - Lebrikizumab (Leb) Q2W
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.000069
Method	Mixed models analysis
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.1
upper limit	-3.9
Variability estimate	Standard error of the mean
Dispersion value	1.52

Secondary: Pharmacokinetics (PK): Average Serum Concentration of Lebrikizumab at Week 52

End point title	Pharmacokinetics (PK): Average Serum Concentration of Lebrikizumab at Week 52
End point description:	
PK: Average serum concentration of lebrikizumab at the Week 52 trough timepoint. Serum concentration is a combined measure obtained from Baseline, Week 4, Week 16, Week 32, Week 52 and average measure was reported at week 52.	
APD: All participants who were randomly assigned to lebrikizumab 250 mg Q2W at Baseline visit and randomly reassigned to lebrikizumab 250 mg Q2W, lebrikizumab 250 mg Q4W, or placebo at Week 16 and had evaluable PK data at Week 52. The 250 mg Q2W PK population also includes any placebo participants entering the Escape Arm at W16 and participants in the Maintenance Period entering the Escape Arm from 250 mg Q2W dosing.	
End point type	Secondary
End point timeframe:	
Predose: Baseline, Week 4, Week 16, Week 32, Week 52	

End point values	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: micrograms per milliliter (ug/mL)				
arithmetic mean (standard deviation)	40.7 (± 23.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continued to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score)

End point title	Percentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continued to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score)
-----------------	---

End point description:

89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).

The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.

Analysis Population Description (APD): All participants who were randomly assigned to lebrikizumab 250 mg Q2W at Baseline visit and randomly reassigned to lebrikizumab 250 mg Q2W, lebrikizumab 250 mg Q4W, or placebo at Week 16 and received at least 1 dose of the study treatment during the Maintenance Period.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 52

End point values	Maintenance - Lebrikizumab Responder/Placebo	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	30	62	61	
Units: percentage of participants				
number (confidence interval 95%)	61.3 (42.3 to 80.4)	79.2 (68.0 to 90.4)	79.2 (67.6 to 90.8)	

Statistical analyses

Statistical analysis title	EASI-75 at Week 52
Comparison groups	Maintenance - Lebrikizumab Responder/Placebo v Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.072375
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	17.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	38.1

Statistical analysis title	EASI-75 at Week 52
Comparison groups	Maintenance - Lebrikizumab Responder/Placebo v Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.106653
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	17.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	39.5

Secondary: Percentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥ 2 -point Improvement From Baseline at Week 16 Who Continue to Exhibit and IGA 0 or 1 and a ≥ 2 -point Improvement From Baseline at Week 52

End point title	Percentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥ 2 -point Improvement From Baseline at Week 16 Who Continue to Exhibit and IGA 0 or 1 and a ≥ 2 -point Improvement From Baseline at Week 52
-----------------	---

End point description:

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

APD: All participants who were randomized to Lebrikizumab 250 mg Q2W at Baseline Visit and re-randomized to Lebrikizumab 250 mg Q2W, Lebrikizumab 250 mg Q4W or placebo at Week 16 and received at least 1 dose of study treatment during the maintenance period.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 52

End point values	Maintenance - Lebrikizumab Responder/Placebo	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	30	63	62	
Units: percentage of participants				
number (confidence interval 95%)	46.5 (24.4 to 68.7)	74.2 (60.5 to 88.0)	75.8 (62.9 to 88.7)	

Statistical analyses

Statistical analysis title	IGA 0 or 1 and a ≥ 2 -point Improvement
Comparison groups	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W v Maintenance - Lebrikizumab Responder/Placebo
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.029857
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	28
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.8
upper limit	53.2

Statistical analysis title	IGA 0 or 1 and a ≥ 2 -point Improvement
Comparison groups	Maintenance - Lebrikizumab Responder/Placebo v Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.019744
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	29

Confidence interval	
level	95 %
sides	2-sided
lower limit	4.6
upper limit	53.3

Secondary: Percentage of Participants From Those With a Pruritus NRS of ≥ 4 -points at Baseline Re-randomized Having Achieved ≥ 4 -point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥ 4 -point Reduction From Baseline at Week 52

End point title	Percentage of Participants From Those With a Pruritus NRS of ≥ 4 -points at Baseline Re-randomized Having Achieved ≥ 4 -point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥ 4 -point Reduction From Baseline at Week 52
-----------------	---

End point description:

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

APD: All participants who were randomized to Lebrikizumab 250 mg Q2W at Baseline Visit and re-randomized to Lebrikizumab 250 mg Q2W, Lebrikizumab 250 mg Q4W or placebo at Week 16 and received at least 1 dose of study treatment during the maintenance period.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 52

End point values	Maintenance - Lebrikizumab Responder/Placebo	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	29	38	
Units: percentage of participants				
number (confidence interval 95%)	65.4 (41.5 to 89.3)	80.4 (63.5 to 97.3)	81.2 (68.0 to 94.3)	

Statistical analyses

Statistical analysis title	NRS ≥ 4 -point Reduction From Baseline at Week 52
Comparison groups	Maintenance - Lebrikizumab Responder/Placebo v Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W
Number of subjects included in analysis	46
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.268265
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	15.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.2
upper limit	43.8

Statistical analysis title	NRS \geq 4-point Reduction From Baseline at Week 52
Comparison groups	Maintenance - Lebrikizumab Responder/Placebo v Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Number of subjects included in analysis	55
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.192776
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	16.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.4
upper limit	42.7

Secondary: Percentage of Participants From Those With a Pruritus NRS of \geq 5-points at Baseline Re-randomized Having Achieved \geq 4-point Reduction From Baseline at Week 16 Who Continue to Exhibit \geq 4-point Reduction From Baseline at Week 52

End point title	Percentage of Participants From Those With a Pruritus NRS of \geq 5-points at Baseline Re-randomized Having Achieved \geq 4-point Reduction From Baseline at Week 16 Who Continue to Exhibit \geq 4-point Reduction From Baseline at Week 52
-----------------	--

End point description:

Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

APD: All participants who were randomized to Lebrikizumab 250 mg Q2W at Baseline Visit and re-randomized to Lebrikizumab 250 mg Q2W, Lebrikizumab 250 mg Q4W or placebo at Week 16 and received at least 1 dose of study treatment during the maintenance period.

End point type	Secondary
End point timeframe:	
Baseline to Week 52	

End point values	Maintenance - Lebrikizumab Responder/Placebo	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	28	38	
Units: percentage of participants				

number (confidence interval 95%)	65.4 (41.5 to 89.3)	83.3 (66.7 to 99.9)	81.2 (68.0 to 94.3)	
----------------------------------	---------------------	---------------------	---------------------	--

Statistical analyses

Statistical analysis title	NRS \geq 4-point Reduction From Baseline at Week 52
Comparison groups	Maintenance - Lebrikizumab Responder/Placebo v Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W
Number of subjects included in analysis	45
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.185361
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	18.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.3
upper limit	46.6

Statistical analysis title	NRS \geq 4-point Reduction From Baseline at Week 52
Comparison groups	Maintenance - Lebrikizumab Responder/Placebo v Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Number of subjects included in analysis	55
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.192776
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	16.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.4
upper limit	42.7

Secondary: Percent Change in SCORAD (Having Achieved EASI-75 at Week 16) From Baseline at Week 52

End point title	Percent Change in SCORAD (Having Achieved EASI-75 at Week 16) From Baseline at Week 52
-----------------	--

End point description:

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild,

2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), & subjective symptoms (C: 0-20) combine using $A/5 + 7*B/2 + C$ to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease.

APD: All participants who were randomized to Lebrikizumab 250 mg Q2W at Baseline Visit and re-randomized to Lebrikizumab 250 mg Q2W, Lebrikizumab 250 mg Q4W or placebo at Week 16 and received at least 1 dose of study treatment during the maintenance period.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 52

End point values	Maintenance - Lebrikizumab Responder/Placebo	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	29 ^[5]	59 ^[6]	60 ^[7]	
Units: Percent Change				
least squares mean (standard error)	-69.65 (± 3.972)	-71.39 (± 2.870)	-75.28 (± 2.818)	

Notes:

[5] - Missing Values were imputed using LOCF method.

[6] - Missing Values were imputed using LOCF method.

[7] - Missing Values were imputed using LOCF method.

Statistical analyses

Statistical analysis title	Percent Change in SCORAD
Comparison groups	Maintenance - Lebrikizumab Responder/Placebo v Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.714208
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-1.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.75
upper limit	7.66
Variability estimate	Standard error of the mean
Dispersion value	4.756

Statistical analysis title	Percent Change in SCORAD
----------------------------	--------------------------

Comparison groups	Maintenance - Lebrikizumab Responder/Placebo v Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.237855
Method	ANCOVA
Parameter estimate	LS Mean Difference (Final Values)
Point estimate	-5.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.01
upper limit	3.76
Variability estimate	Standard error of the mean
Dispersion value	4.748

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 52

Adverse event reporting additional description:

All randomized participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.1
--------------------	------

Reporting groups

Reporting group title	Induction Period - Lebrikizumab Q2W
-----------------------	-------------------------------------

Reporting group description:

Induction Period (Baseline-Week 16):

500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.

Reporting group title	Induction Period - Placebo
-----------------------	----------------------------

Reporting group description:

Induction Period (Baseline-Week 16):

Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.

Reporting group title	Maintenance - Lebrikizumab Responder/Placebo
-----------------------	--

Reporting group description:

Maintenance Blinded Period (Week 16 to Week 52): One SC injection of Placebo Q2W.

Reporting group title	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q2W
-----------------------	---

Reporting group description:

Maintenance Blinded Period (Week 16 to Week 52): One 250 mg Lebrikizumab SC injection Q2W.

Reporting group title	Maintenance - Lebrikizumab Responder/Lebrikizumab 250 Q4W
-----------------------	---

Reporting group description:

Maintenance Blinded Period (Week 16-Week 52):

One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and two placebo SC injections on Week 18.

One 250 mg Lebrikizumab SC injection Every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.

One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.

Reporting group title	Maintenance - Placebo Responder/ Placebo
-----------------------	--

Reporting group description:

Maintenance Blinded Period (Week 16 to Week 52): One SC injection of Placebo Q2W.

Reporting group title	Maintenance - Placebo Responder/ Lebrikizumab 250 Q4W
-----------------------	---

Reporting group description:

Maintenance Blinded Period (Week 16 to Week 52):

One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and two placebo SC injections on Week 18.

One 250 mg Lebrikizumab SC injection Every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.

One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50.

Reporting group title	Maintenance - Placebo Responder/Lebrikizumab 250 Q2W
-----------------------	--

Reporting group description:

Maintenance Blinded Period (Week 16 to Week 52): One 250 mg Lebrikizumab SC injection Q2W.

Reporting group title	Escape Arm Week 16 - Maintenance OL - PBO NR/Leb 250 Q2W
-----------------------	--

Reporting group description:

Maintenance Escape Period (Week 16 to Week 52): One 250 mg Lebrikizumab SC injection Q2W.

Reporting group title	Escape Arm Week 16 - Maintenance OL - Leb NR/Leb 250 Q2W
Reporting group description:	
Maintenance Escape Period (Week 16 to Week 52): One 250 mg Lebrikizumab SC injection Q2W.	
Reporting group title	Escape Arm Week 24 to 48 - Maintenance OL - Leb 250 Q2W
Reporting group description:	
Maintenance Escape Period (Week 24 to Week 48): One 250 mg Lebrikizumab SC injection Q2W.	

Serious adverse events	Induction Period - Lebrikizumab Q2W	Induction Period - Placebo	Maintenance - Lebrikizumab Responder/Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 282 (2.13%)	1 / 141 (0.71%)	0 / 32 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
accidental overdose			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thermal burn			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
myocardial infarction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
carpal tunnel syndrome			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions			
oedema peripheral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
dysmenorrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[1]	0 / 141 (0.00%)	0 / 73 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
micromastia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
cholecystitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
somatic symptom disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
synovitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
covid-19			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cellulitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sepsis			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Maintenance - Lebrikizumab Responder/Lebrikizu mab 250 Q2W	Maintenance - Lebrikizumab Responder/Lebrikizu mab 250 Q4W	Maintenance - Placebo Responder/ Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 62 (0.00%)	2 / 63 (3.17%)	1 / 4 (25.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
accidental overdose			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thermal burn			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
myocardial infarction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
carpal tunnel syndrome			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

oedema peripheral alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 62 (0.00%) 0 / 0 0 / 0	0 / 63 (0.00%) 0 / 0 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0
Reproductive system and breast disorders dysmenorrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[1] occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 28 (0.00%) 0 / 0 0 / 0	0 / 38 (0.00%) 0 / 0 0 / 0	0 / 2 (0.00%) 0 / 0 0 / 0
micromastia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 62 (0.00%) 0 / 0 0 / 0	0 / 63 (0.00%) 0 / 0 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0
Hepatobiliary disorders cholecystitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 62 (0.00%) 0 / 0 0 / 0	1 / 63 (1.59%) 0 / 1 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0
Psychiatric disorders somatic symptom disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 62 (0.00%) 0 / 0 0 / 0	1 / 63 (1.59%) 0 / 1 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
synovitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
covid-19			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cellulitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sepsis			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Maintenance - Placebo Responder/ Lebrikizumab 250 Q4W	Maintenance - Placebo Responder/Lebrikizu mab 250 Q2W	Escape Arm Week 16 - Maintenance OL - PBO NR/Leb 250 Q2W
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
accidental overdose			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
thermal burn			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
myocardial infarction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
carpal tunnel syndrome			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

oedema peripheral alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 10 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	0 / 96 (0.00%) 0 / 0 0 / 0
Reproductive system and breast disorders dysmenorrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[1] occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 4 (0.00%) 0 / 0 0 / 0	0 / 45 (0.00%) 0 / 0 0 / 0
micromastia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 10 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	1 / 96 (1.04%) 0 / 1 0 / 0
Hepatobiliary disorders cholecystitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 10 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	0 / 96 (0.00%) 0 / 0 0 / 0
Psychiatric disorders somatic symptom disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 10 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	0 / 96 (0.00%) 0 / 0 0 / 0
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
arthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
synovitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
covid-19			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cellulitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sepsis			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Escape Arm Week 16 - Maintenance OL - Leb NR/Leb 250 Q2W	Escape Arm Week 24 to 48 - Maintenance OL - Leb 250 Q2W	
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 106 (3.77%)	0 / 18 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Injury, poisoning and procedural complications			
accidental overdose			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
thermal burn			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
myocardial infarction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
carpal tunnel syndrome			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			

oedema peripheral alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	0 / 18 (0.00%) 0 / 0 0 / 0	
Reproductive system and breast disorders dysmenorrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[1] occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 43 (2.33%) 0 / 1 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	
micromastia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	0 / 18 (0.00%) 0 / 0 0 / 0	
Hepatobiliary disorders cholecystitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	0 / 18 (0.00%) 0 / 0 0 / 0	
Psychiatric disorders somatic symptom disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	0 / 18 (0.00%) 0 / 0 0 / 0	
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
arthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
synovitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
covid-19			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cellulitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
sepsis			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Induction Period - Lebrikizumab Q2W	Induction Period - Placebo	Maintenance - Lebrikizumab Responder/Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	127 / 282 (45.04%)	73 / 141 (51.77%)	15 / 32 (46.88%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
cutaneous t-cell lymphoma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
haemangioma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
histiocytic necrotising lymphadenitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
penile squamous cell carcinoma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[2]	0 / 141 (0.00%)	0 / 68 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
skin papilloma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			

hypertension alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	3 / 282 (1.06%) 3	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
peripheral venous disease alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 1	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
General disorders and administration site conditions			
administration site reaction alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 1	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
asthenia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 2	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
chest discomfort alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
chills alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 2	0 / 32 (0.00%) 0
fatigue alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	2 / 282 (0.71%) 2	1 / 141 (0.71%) 1	1 / 32 (3.13%) 1
hyperthermia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 1	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
injection site bruising alternative dictionary used:			

MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	2	0
injection site erythema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	2	0	0
injection site pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	2 / 141 (1.42%)	0 / 32 (0.00%)
occurrences (all)	2	6	0
injection site pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
injection site reaction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
injection site swelling			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
non-cardiac chest pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
oedema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
oedema peripheral			
alternative dictionary used: MedDRA 24.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pyrexia</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>swelling face</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>vaccination site pain</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 282 (1.06%)</p> <p>4</p> <p>1 / 282 (0.35%)</p> <p>1</p> <p>0 / 282 (0.00%)</p> <p>0</p> <p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p> <p>0 / 141 (0.00%)</p> <p>0</p> <p>0 / 141 (0.00%)</p> <p>0</p> <p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p> <p>1 / 32 (3.13%)</p> <p>1</p> <p>0 / 32 (0.00%)</p> <p>0</p> <p>0 / 32 (0.00%)</p> <p>0</p>
<p>Immune system disorders</p> <p>food allergy</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>hypersensitivity</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>seasonal allergy</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p> <p>1 / 282 (0.35%)</p> <p>1</p> <p>0 / 282 (0.00%)</p> <p>0</p>	<p>1 / 141 (0.71%)</p> <p>1</p> <p>0 / 141 (0.00%)</p> <p>0</p> <p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p> <p>0 / 32 (0.00%)</p> <p>0</p> <p>0 / 32 (0.00%)</p> <p>0</p>
<p>Reproductive system and breast disorders</p> <p>benign prostatic hyperplasia</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed^[3]</p> <p>occurrences (all)</p> <p>cervical dysplasia</p> <p>alternative dictionary used: MedDRA 24.1</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 68 (0.00%)</p> <p>0</p>	<p>0 / 11 (0.00%)</p> <p>0</p>

subjects affected / exposed ^[4]	0 / 141 (0.00%)	0 / 73 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
dysmenorrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[5]	3 / 141 (2.13%)	0 / 73 (0.00%)	0 / 21 (0.00%)
occurrences (all)	5	0	0
galactorrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
heavy menstrual bleeding			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[6]	1 / 141 (0.71%)	0 / 73 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
vaginal haemorrhage			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[7]	0 / 141 (0.00%)	0 / 73 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
asthma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	3 / 282 (1.06%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	3	1	0
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
cough			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	1	1	0
dyspnoea			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
epistaxis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
nasal congestion			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
nasal inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
oropharyngeal pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
paranasal sinus inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
reflux laryngitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
rhinitis allergic			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	2	0	0
rhinorrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0

sinus congestion alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
sleep apnoea syndrome alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
Psychiatric disorders anxiety alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	4 / 282 (1.42%) 6	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
attention deficit hyperactivity disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
delirium alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
depression alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	2 / 282 (0.71%) 2	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
insomnia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 1	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
persistent depressive disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
sleep disorder alternative dictionary used:			

MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
stress			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Investigations			
alanine aminotransferase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
blood creatinine increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
blood lactate dehydrogenase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
blood phosphorus decreased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
blood potassium increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
blood pressure increased			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
blood urea increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
blood uric acid increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
eosinophil count increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
haemoglobin urine present			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
hepatic enzyme increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
lymphocyte count decreased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
lymphocyte morphology abnormal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
neutrophil count decreased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0

neutrophil count increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
nitrite urine present			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
platelet count increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
protein urine present			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
smear cervix abnormal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[8]	0 / 141 (0.00%)	0 / 73 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
strongyloides test positive			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
transaminases increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
urine bilirubin increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
urine leukocyte esterase positive			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
weight increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
arthropod bite			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
back injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
burns second degree			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
contusion			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
epicondylitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
head injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
ligament sprain			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
meniscus injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
muscle strain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
overdose			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
pelvic fracture			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
post procedural inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
procedural pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
radius fracture			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
sunburn			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0

thermal burn alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
tooth fracture alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
tooth injury alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 1	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
upper limb fracture alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
vaccination complication alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
Cardiac disorders angina pectoris alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 1	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
palpitations alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
tachycardia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
Nervous system disorders			

carpal tunnel syndrome			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
dizziness			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	5	1	0
dysgeusia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
epilepsy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
essential tremor			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
headache			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	9 / 282 (3.19%)	2 / 141 (1.42%)	0 / 32 (0.00%)
occurrences (all)	10	2	0
hypersomnia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
migraine			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
post herpetic neuralgia			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
presyncope			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
radiculopathy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
sciatica			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
seizure			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
syncope			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
eosinophilia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	2 / 141 (1.42%)	0 / 32 (0.00%)
occurrences (all)	1	2	0
erythropenia			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
immune thrombocytopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
iron deficiency anaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
leukopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
lymphadenopathy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
lymphopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
neutropenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
splenomegaly			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
thrombocytopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	2	0	0

<p>Ear and labyrinth disorders</p> <p>deafness unilateral</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>vertigo</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>Eye disorders</p> <p>angle closure glaucoma</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>blepharitis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 282 (1.06%)</p> <p>3</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>cataract</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>chalazion</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 282 (0.71%)</p> <p>2</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>conjunctival disorder</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>conjunctival hyperaemia</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 282 (0.35%)</p> <p>1</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>conjunctivitis allergic</p>			

alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	7 / 282 (2.48%)	1 / 141 (0.71%)	1 / 32 (3.13%)
occurrences (all)	7	1	1
dry eye			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	2 / 141 (1.42%)	0 / 32 (0.00%)
occurrences (all)	1	2	0
eye irritation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	2	0	0
eye pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
eye pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
eyelid irritation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
eyelid oedema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
eyelids pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
glaucomatocyclitic crises			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
keratitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
keratoconus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
lacrimation increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
meibomian gland dysfunction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
ocular hyperaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
pupils unequal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
vernal keratoconjunctivitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
vision blurred			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0

visual impairment alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 1	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
Gastrointestinal disorders			
abdominal discomfort alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
abdominal pain alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 1	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
anal haemorrhage alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
constipation alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
dental caries alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
diarrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	1 / 32 (3.13%) 1
gastric polyps alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
gastrointestinal inflammation alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
mouth ulceration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
nausea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	2 / 141 (1.42%)	0 / 32 (0.00%)
occurrences (all)	0	2	0
odynophagia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
toothache			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	1	1	0
vomiting			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	1	1	0
Hepatobiliary disorders			
cholelithiasis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
hepatic steatosis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
non-alcoholic steatohepatitis			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
acne			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
alopecia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
alopecia areata			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
dermal cyst			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
dermatitis atopic			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	16 / 282 (5.67%)	30 / 141 (21.28%)	4 / 32 (12.50%)
occurrences (all)	17	33	4
dermatitis contact			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
drug eruption			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
dyshidrotic eczema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
eczema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
erythema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
ingrowing nail			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
milia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
miliaria			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
papule			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
photosensitivity reaction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0

pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	3 / 282 (1.06%)	6 / 141 (4.26%)	0 / 32 (0.00%)
occurrences (all)	3	7	0
rash			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
seborrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
seborrhoeic dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	2	1	0
skin burning sensation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
skin lesion inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
solar dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
solar lentigo			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
urticaria			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
Renal and urinary disorders cystitis noninfective alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 282 (0.35%) 1	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
haematuria alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
micturition disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
nephrolithiasis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
Endocrine disorders hyperparathyroidism secondary alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	1 / 141 (0.71%) 1	0 / 32 (0.00%) 0
hyperthyroidism alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 282 (0.00%) 0	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	2 / 282 (0.71%) 2	0 / 141 (0.00%) 0	0 / 32 (0.00%) 0
arthritis alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
back pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	1 / 141 (0.71%)	1 / 32 (3.13%)
occurrences (all)	2	1	1
bursitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	1	1	0
growing pains			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
muscle twitching			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
musculoskeletal chest pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
musculoskeletal stiffness			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
myalgia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	2	0
neck pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0

<p>osteoarthritis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>pain in extremity</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 282 (0.35%)</p> <p>1</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>periarthritis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>rotator cuff syndrome</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>spinal osteoarthritis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>synovial cyst</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p>	<p>0 / 32 (0.00%)</p> <p>0</p>
<p>Infections and infestations</p> <p>abscess limb</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>abscess neck</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>bacterial vaginosis</p> <p>alternative dictionary used: MedDRA 24.1</p>	<p>0 / 282 (0.00%)</p> <p>0</p> <p>0 / 282 (0.00%)</p> <p>0</p>	<p>0 / 141 (0.00%)</p> <p>0</p> <p>1 / 141 (0.71%)</p> <p>1</p>	<p>0 / 32 (0.00%)</p> <p>0</p> <p>0 / 32 (0.00%)</p> <p>0</p>

subjects affected / exposed ^[9]	1 / 141 (0.71%)	0 / 73 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
bronchitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	2	0	0
covid-19			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	5 / 282 (1.77%)	3 / 141 (2.13%)	1 / 32 (3.13%)
occurrences (all)	5	3	1
cellulitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
chest wall abscess			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
conjunctivitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	21 / 282 (7.45%)	4 / 141 (2.84%)	1 / 32 (3.13%)
occurrences (all)	23	4	1
conjunctivitis bacterial			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
conjunctivitis viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
ear infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0

ecthyma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
eczema herpeticum			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	1 / 32 (3.13%)
occurrences (all)	0	1	1
endophthalmitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
folliculitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	3 / 282 (1.06%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	3	1	0
fungal skin infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
furuncle			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	2 / 141 (1.42%)	0 / 32 (0.00%)
occurrences (all)	0	3	0
gastroenteritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	3	0	0
gastroenteritis viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 282 (0.71%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	2	0	0
genital herpes simplex			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
gingivitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
helicobacter infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
herpes dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
herpes zoster			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
impetigo			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	4 / 282 (1.42%)	2 / 141 (1.42%)	0 / 32 (0.00%)
occurrences (all)	4	2	0
infected cyst			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
influenza			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	1 / 32 (3.13%)
occurrences (all)	1	0	1

labyrinthitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	1 / 32 (3.13%)
occurrences (all)	0	0	1
localised infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
lower respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
myringitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
nasopharyngitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	11 / 282 (3.90%)	4 / 141 (2.84%)	2 / 32 (6.25%)
occurrences (all)	11	4	2
ophthalmic herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
oral herpes			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	9 / 282 (3.19%)	5 / 141 (3.55%)	0 / 32 (0.00%)
occurrences (all)	9	10	0
otitis media			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
paronychia			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
peritonsillar abscess			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
pertussis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
pharyngitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
pharyngitis streptococcal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
pneumonia aspiration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
postoperative wound infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
respiratory tract infection viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
secondary syphilis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0

sinusitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
skin infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	2 / 141 (1.42%)	0 / 32 (0.00%)
occurrences (all)	1	2	0
tinea capitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
tinea cruris			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
tinea versicolour			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
tonsillitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	2 / 141 (1.42%)	0 / 32 (0.00%)
occurrences (all)	1	2	0
tooth abscess			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
tooth infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 282 (0.35%)	2 / 141 (1.42%)	3 / 32 (9.38%)
occurrences (all)	1	3	3
urinary tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	1 / 141 (0.71%)	2 / 32 (6.25%)
occurrences (all)	1	1	2
vaginal infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[10]	0 / 141 (0.00%)	1 / 73 (1.37%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
viral pericarditis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
viral upper respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
vulvovaginal candidiasis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[11]	2 / 141 (1.42%)	0 / 73 (0.00%)	0 / 21 (0.00%)
occurrences (all)	2	0	0
Metabolism and nutrition disorders			
decreased appetite			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
dehydration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
dyslipidaemia			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
hypercholesterolaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
hyperlipidaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
hypokalaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 282 (0.35%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	1	0	0
obesity			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	0 / 141 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
vitamin d deficiency			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 282 (0.00%)	1 / 141 (0.71%)	0 / 32 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	Maintenance - Lebrikizumab Responder/Lebrikizu mab 250 Q2W	Maintenance - Lebrikizumab Responder/Lebrikizu mab 250 Q4W	Maintenance - Placebo Responder/ Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 62 (40.32%)	32 / 63 (50.79%)	2 / 4 (50.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
cutaneous t-cell lymphoma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
haemangioma			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
histiocytic necrotising lymphadenitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
penile squamous cell carcinoma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[2]	0 / 34 (0.00%)	0 / 25 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
skin papilloma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
hypertension			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 62 (3.23%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
peripheral venous disease			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
administration site reaction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
asthenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
chest discomfort			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
chills			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
fatigue			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
hyperthermia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
injection site bruising			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
injection site erythema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
injection site pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
injection site pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
injection site reaction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

injection site swelling alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
non-cardiac chest pain alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
oedema alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
oedema peripheral alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
pyrexia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
swelling face alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
vaccination site pain alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
Immune system disorders food allergy alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	1 / 63 (1.59%) 1	0 / 4 (0.00%) 0
hypersensitivity alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
seasonal allergy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
benign prostatic hyperplasia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[3]	0 / 34 (0.00%)	1 / 25 (4.00%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
cervical dysplasia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[4]	0 / 28 (0.00%)	0 / 38 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
dysmenorrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[5]	0 / 28 (0.00%)	0 / 38 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
galactorrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
heavy menstrual bleeding			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[6]	0 / 28 (0.00%)	0 / 38 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
vaginal haemorrhage			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[7]	0 / 28 (0.00%)	0 / 38 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
asthma			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
cough			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
dyspnoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
epistaxis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
nasal congestion			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
nasal inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
oropharyngeal pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
paranasal sinus inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

reflux laryngitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
rhinitis allergic alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
rhinorrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
sinus congestion alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
sleep apnoea syndrome alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
Psychiatric disorders anxiety alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
attention deficit hyperactivity disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
delirium alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
depression alternative dictionary used:			

MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
insomnia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
persistent depressive disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
sleep disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
stress			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Investigations			
alanine aminotransferase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	2 / 63 (3.17%)	0 / 4 (0.00%)
occurrences (all)	1	2	0
blood creatinine increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
blood lactate dehydrogenase increased			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
blood phosphorus decreased alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
blood potassium increased alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
blood pressure increased alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
blood urea increased alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
blood uric acid increased alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
eosinophil count increased alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
haemoglobin urine present alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
hepatic enzyme increased alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

lymphocyte count decreased alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
lymphocyte morphology abnormal alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
neutrophil count decreased alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
neutrophil count increased alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
nitrite urine present alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
platelet count increased alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
protein urine present alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
smear cervix abnormal alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[8] occurrences (all)	0 / 28 (0.00%) 0	0 / 38 (0.00%) 0	0 / 2 (0.00%) 0
strongyloides test positive alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
transaminases increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
urine bilirubin increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
urine leukocyte esterase positive			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
weight increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Injury, poisoning and procedural complications			
arthropod bite			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
back injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
burns second degree			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
contusion			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	2 / 63 (3.17%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
epicondylitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
head injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ligament sprain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
meniscus injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
muscle strain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
overdose			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
pelvic fracture			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
post procedural inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

procedural pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
radius fracture			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
sunburn			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
thermal burn			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
tooth fracture			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
tooth injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
upper limb fracture			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
vaccination complication			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			

<p>angina pectoris</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>palpitations</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>tachycardia</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 62 (1.61%)</p> <p>1</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>Nervous system disorders</p> <p>carpal tunnel syndrome</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dizziness</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dysgeusia</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>epilepsy</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>essential tremor</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>headache</p> <p>alternative dictionary used: MedDRA 24.1</p>	<p>0 / 62 (0.00%)</p> <p>0</p> <p>0 / 62 (0.00%)</p> <p>0</p> <p>0 / 62 (0.00%)</p> <p>0</p> <p>0 / 62 (0.00%)</p> <p>0</p> <p>0 / 62 (0.00%)</p> <p>0</p> <p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p> <p>0 / 63 (0.00%)</p> <p>0</p> <p>0 / 63 (0.00%)</p> <p>0</p> <p>0 / 63 (0.00%)</p> <p>0</p> <p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p>

subjects affected / exposed	0 / 62 (0.00%)	2 / 63 (3.17%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
hypersomnia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
migraine			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
post herpetic neuralgia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
presyncope			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
radiculopathy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
sciatica			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
seizure			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
syncope			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
eosinophilia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
erythropenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
immune thrombocytopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
iron deficiency anaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
leukopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
lymphadenopathy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	2
lymphopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
neutropenia			
alternative dictionary used: MedDRA 24.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>splenomegaly</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>1 / 4 (25.00%)</p> <p>1</p>
<p>thrombocytopenia</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>Ear and labyrinth disorders</p> <p>deafness unilateral</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>vertigo</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>Eye disorders</p> <p>angle closure glaucoma</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>blepharitis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 62 (1.61%)</p> <p>1</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>cataract</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 62 (0.00%)</p> <p>0</p>	<p>0 / 63 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>
<p>chalazion</p> <p>alternative dictionary used: MedDRA 24.1</p>			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
conjunctival disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
conjunctival hyperaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
conjunctivitis allergic			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	3 / 63 (4.76%)	0 / 4 (0.00%)
occurrences (all)	1	3	0
dry eye			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
eye irritation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
eye pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
eye pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
eyelid irritation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0

eyelid oedema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	3	0
eyelids pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
glaucomatocyclitic crises			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
keratitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
keratoconus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
lacrimation increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
meibomian gland dysfunction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
ocular hyperaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
pupils unequal			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
vernal keratoconjunctivitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
vision blurred			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
visual impairment			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
abdominal discomfort			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
abdominal pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
anal haemorrhage			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
constipation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
dental caries			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
diarrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
gastric polyps			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
gastrointestinal inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
mouth ulceration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
nausea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
odynophagia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
toothache			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
vomiting			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Hepatobiliary disorders cholelithiasis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) hepatic steatosis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) non-alcoholic steatohepatitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0 0 / 62 (0.00%) 0 0 / 62 (0.00%) 0	0 / 63 (0.00%) 0 1 / 63 (1.59%) 1 0 / 63 (0.00%) 0	0 / 4 (0.00%) 0 0 / 4 (0.00%) 0 0 / 4 (0.00%) 0
Skin and subcutaneous tissue disorders acne alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) alopecia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) alopecia areata alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) dermal cyst alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) dermatitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) dermatitis atopic	0 / 62 (0.00%) 0 0 / 62 (0.00%) 0 0 / 62 (0.00%) 0 0 / 62 (0.00%) 0 0 / 62 (0.00%) 0	0 / 63 (0.00%) 0 1 / 63 (1.59%) 1 0 / 63 (0.00%) 0 0 / 63 (0.00%) 0 0 / 63 (0.00%) 0	0 / 4 (0.00%) 0 0 / 4 (0.00%) 0 0 / 4 (0.00%) 0 0 / 4 (0.00%) 0

alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 62 (3.23%)	4 / 63 (6.35%)	2 / 4 (50.00%)
occurrences (all)	2	4	2
dermatitis contact			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
drug eruption			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
dyshidrotic eczema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
eczema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
erythema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
ingrowing nail			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
milia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
miliaria			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
papule			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
photosensitivity reaction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
rash			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
seborrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
seborrhoeic dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
skin burning sensation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
skin lesion inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

solar dermatitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
solar lentigo alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	1 / 63 (1.59%) 1	0 / 4 (0.00%) 0
urticaria alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	1 / 63 (1.59%) 1	0 / 4 (0.00%) 0
Renal and urinary disorders cystitis noninfective alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
haematuria alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
micturition disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	1 / 63 (1.59%) 1	0 / 4 (0.00%) 0
nephrolithiasis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
Endocrine disorders hyperparathyroidism secondary alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
hyperthyroidism			

alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
arthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
back pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
bursitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
growing pains			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
muscle twitching			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
musculoskeletal chest pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
musculoskeletal stiffness			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
myalgia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
neck pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
osteoarthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
pain in extremity			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
periarthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
rotator cuff syndrome			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
spinal osteoarthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
synovial cyst			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Infections and infestations abscess limb alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
abscess neck alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
bacterial vaginosis alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[9] occurrences (all)	0 / 28 (0.00%) 0	0 / 38 (0.00%) 0	0 / 2 (0.00%) 0
bronchitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
covid-19 alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	2 / 62 (3.23%) 2	8 / 63 (12.70%) 9	0 / 4 (0.00%) 0
cellulitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
chest wall abscess alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
conjunctivitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	1 / 63 (1.59%) 1	0 / 4 (0.00%) 0
conjunctivitis bacterial alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
conjunctivitis viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ear infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ecthyma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
eczema herpeticum			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
endophthalmitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
folliculitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
fungal skin infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
furuncle			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

gastroenteritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
gastroenteritis viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
genital herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
gingivitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
helicobacter infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
herpes dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
herpes zoster			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
impetigo			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 62 (1.61%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
infected cyst			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
influenza			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
labyrinthitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
localised infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
lower respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
myringitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
nasopharyngitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 62 (3.23%)	6 / 63 (9.52%)	0 / 4 (0.00%)
occurrences (all)	2	6	0
ophthalmic herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

oral herpes			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	2 / 63 (3.17%)	0 / 4 (0.00%)
occurrences (all)	1	2	0
otitis media			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
paronychia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
peritonsillar abscess			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
pertussis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
pharyngitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
pharyngitis streptococcal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
pneumonia aspiration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
postoperative wound infection			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
respiratory tract infection viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
secondary syphilis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
sinusitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	2 / 63 (3.17%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
skin infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
tinea capitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
tinea cruris			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
tinea versicolour			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
tonsillitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

tooth abscess			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
tooth infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
urinary tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 62 (0.00%)	1 / 63 (1.59%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
vaginal infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[10]	0 / 28 (0.00%)	0 / 38 (0.00%)	0 / 2 (0.00%)
occurrences (all)	0	0	0
viral pericarditis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
viral upper respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 62 (1.61%)	0 / 63 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
vulvovaginal candidiasis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[11]	0 / 28 (0.00%)	1 / 38 (2.63%)	0 / 2 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			

decreased appetite alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
dehydration alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 62 (1.61%) 1	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
dyslipidaemia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
hypercholesterolaemia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
hyperlipidaemia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
hypokalaemia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
obesity alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0
vitamin d deficiency alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 62 (0.00%) 0	0 / 63 (0.00%) 0	0 / 4 (0.00%) 0

Non-serious adverse events	Maintenance - Placebo Responder/ Lebrikizumab 250 Q4W	Maintenance - Placebo Responder/Lebrikizu mab 250 Q2W	Escape Arm Week 16 - Maintenance OL - PBO NR/Leb 250 Q2W
-----------------------------------	--	--	---

Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 10 (40.00%)	3 / 10 (30.00%)	51 / 96 (53.13%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
cutaneous t-cell lymphoma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
haemangioma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
histiocytic necrotising lymphadenitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
penile squamous cell carcinoma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[2]	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
skin papilloma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
hypertension			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
peripheral venous disease			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			

administration site reaction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
asthenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
chest discomfort			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
chills			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
fatigue			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
hyperthermia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
injection site bruising			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
injection site erythema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
injection site pain			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
injection site pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
injection site reaction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	2 / 96 (2.08%)
occurrences (all)	0	0	3
injection site swelling			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
non-cardiac chest pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
oedema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
oedema peripheral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
pyrexia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
swelling face			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0

vaccination site pain alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	2 / 96 (2.08%) 2
Immune system disorders food allergy alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) hypersensitivity alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) seasonal allergy alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0	0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0	0 / 96 (0.00%) 0 0 / 96 (0.00%) 0 0 / 96 (0.00%) 0
Reproductive system and breast disorders benign prostatic hyperplasia alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[3] occurrences (all) cervical dysplasia alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[4] occurrences (all) dysmenorrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[5] occurrences (all) galactorrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all) heavy menstrual bleeding	0 / 4 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 10 (0.00%) 0	0 / 6 (0.00%) 0 0 / 4 (0.00%) 0 0 / 4 (0.00%) 0 0 / 10 (0.00%) 0	1 / 51 (1.96%) 1 1 / 45 (2.22%) 1 0 / 45 (0.00%) 0 0 / 96 (0.00%) 0

alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[6] occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 45 (0.00%) 0
vaginal haemorrhage alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[7] occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	0 / 45 (0.00%) 0
Respiratory, thoracic and mediastinal disorders asthma alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	1 / 96 (1.04%) 1
chronic obstructive pulmonary disease alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
cough alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	1 / 96 (1.04%) 1
dyspnoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
epistaxis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
nasal congestion alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
nasal inflammation alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
oropharyngeal pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
paranasal sinus inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
reflux laryngitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
rhinitis allergic			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
rhinorrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	0 / 96 (0.00%)
occurrences (all)	0	1	0
sinus congestion			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
sleep apnoea syndrome			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
anxiety			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
attention deficit hyperactivity disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
delirium			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
depression			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
insomnia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
persistent depressive disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
sleep disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
stress			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
Investigations			
alanine aminotransferase increased			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
blood creatinine increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
blood lactate dehydrogenase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
blood phosphorus decreased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
blood potassium increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
blood pressure increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
blood urea increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
blood uric acid increased			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
eosinophil count increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
haemoglobin urine present			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
hepatic enzyme increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
lymphocyte count decreased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
lymphocyte morphology abnormal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
neutrophil count decreased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
neutrophil count increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
nitrite urine present			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0

platelet count increased alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
protein urine present alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
smear cervix abnormal alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[8] occurrences (all)	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0	1 / 45 (2.22%) 1
strongyloides test positive alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
transaminases increased alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	1 / 96 (1.04%) 1
urine bilirubin increased alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
urine leukocyte esterase positive alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
weight increased alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
Injury, poisoning and procedural complications			

arthropod bite			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
back injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
burns second degree			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
contusion			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
epicondylitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
head injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
ligament sprain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
meniscus injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
muscle strain			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
overdose			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
pelvic fracture			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
post procedural inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
procedural pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
radius fracture			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
sunburn			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	1	0	0
thermal burn			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
tooth fracture			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1

tooth injury alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
upper limb fracture alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
vaccination complication alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 10 (10.00%) 2	3 / 96 (3.13%) 3
Cardiac disorders angina pectoris alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
palpitations alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
tachycardia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
Nervous system disorders carpal tunnel syndrome alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
dizziness alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
dysgeusia			

alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
epilepsy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
essential tremor			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
headache			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
hypersomnia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
migraine			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
post herpetic neuralgia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
presyncope			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
radiculopathy			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
sciatica			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
seizure			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
syncope			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
eosinophilia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
erythropenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
immune thrombocytopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	2 / 96 (2.08%)
occurrences (all)	0	0	2
iron deficiency anaemia			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
leukopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
lymphadenopathy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	2 / 96 (2.08%)
occurrences (all)	0	0	3
lymphopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
neutropenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
splenomegaly			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
thrombocytopenia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
Ear and labyrinth disorders			
deafness unilateral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
vertigo			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
Eye disorders			
angle closure glaucoma alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
blepharitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	1 / 96 (1.04%) 1
cataract alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	1 / 96 (1.04%) 1
chalazion alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
conjunctival disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
conjunctival hyperaemia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	0 / 96 (0.00%) 0
conjunctivitis allergic alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 10 (0.00%) 0	6 / 96 (6.25%) 7
dry eye alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
eye irritation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
eye pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
eye pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	2 / 96 (2.08%)
occurrences (all)	0	0	4
eyelid irritation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
eyelid oedema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
eyelids pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
glaucomatocyclitic crises			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
keratitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0

keratoconus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
lacrimation increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
meibomian gland dysfunction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
ocular hyperaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
pupils unequal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
vernal keratoconjunctivitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
vision blurred			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
visual impairment			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			

abdominal discomfort			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
abdominal pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
anal haemorrhage			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
constipation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
dental caries			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
diarrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
gastric polyps			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
gastrointestinal inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
mouth ulceration			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
nausea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
odynophagia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
toothache			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
vomiting			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
cholelithiasis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
hepatic steatosis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
non-alcoholic steatohepatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
acne			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
alopecia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
alopecia areata			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
dermal cyst			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	2 / 96 (2.08%)
occurrences (all)	0	0	2
dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
dermatitis atopic			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	6 / 96 (6.25%)
occurrences (all)	0	0	6
dermatitis contact			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
drug eruption			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
dyshidrotic eczema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0

eczema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
erythema			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
ingrowing nail			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
milia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
miliaria			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	2
papule			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
photosensitivity reaction			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
rash			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
seborrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
seborrhoeic dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
skin burning sensation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
skin lesion inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
solar dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
solar lentigo			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
urticaria			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
cystitis noninfective			
alternative dictionary used: MedDRA 24.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>haematuria</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>1 / 96 (1.04%)</p> <p>1</p>
<p>micturition disorder</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>nephrolithiasis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>Endocrine disorders</p> <p>hyperparathyroidism secondary</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>hyperthyroidism</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>1 / 96 (1.04%)</p> <p>1</p>
<p>Musculoskeletal and connective tissue disorders</p> <p>arthralgia</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>arthritis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>back pain</p> <p>alternative dictionary used: MedDRA 24.1</p>			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
bursitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
growing pains			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
muscle twitching			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
musculoskeletal chest pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
musculoskeletal stiffness			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
myalgia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
neck pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
osteoarthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0

<p>pain in extremity</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>periarthritis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>rotator cuff syndrome</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>1 / 96 (1.04%)</p> <p>1</p>
<p>spinal osteoarthritis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>1 / 96 (1.04%)</p> <p>1</p>
<p>synovial cyst</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>1 / 96 (1.04%)</p> <p>1</p>
Infections and infestations			
<p>abscess limb</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>1 / 10 (10.00%)</p> <p>1</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>abscess neck</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>0 / 96 (0.00%)</p> <p>0</p>
<p>bacterial vaginosis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed^[9]</p> <p>occurrences (all)</p>	<p>0 / 6 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>	<p>1 / 45 (2.22%)</p> <p>1</p>
<p>bronchitis</p> <p>alternative dictionary used: MedDRA 24.1</p>			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
covid-19			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	4 / 96 (4.17%)
occurrences (all)	1	0	4
cellulitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
chest wall abscess			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	1 / 10 (10.00%)	0 / 96 (0.00%)
occurrences (all)	0	1	0
conjunctivitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	9 / 96 (9.38%)
occurrences (all)	0	0	11
conjunctivitis bacterial			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	2 / 96 (2.08%)
occurrences (all)	0	0	2
conjunctivitis viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
ear infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
ecthyma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0

eczema herpeticum			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
endophthalmitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
folliculitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
fungus skin infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
furuncle			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
gastroenteritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
gastroenteritis viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
genital herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
gingivitis			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
helicobacter infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
herpes dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
herpes zoster			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
impetigo			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
infected cyst			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
influenza			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
labyrinthitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0

localised infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
lower respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
myringitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
nasopharyngitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 10 (10.00%)	1 / 10 (10.00%)	2 / 96 (2.08%)
occurrences (all)	1	1	2
ophthalmic herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
oral herpes			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 10 (0.00%)	3 / 96 (3.13%)
occurrences (all)	1	0	4
otitis media			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
paronychia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
peritonsillar abscess			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
pertussis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
pharyngitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
pharyngitis streptococcal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
pneumonia aspiration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
postoperative wound infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
respiratory tract infection viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
secondary syphilis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
sinusitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0

skin infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
tinea capitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
tinea cruris			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
tinea versicolour			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
tonsillitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 10 (10.00%)	1 / 10 (10.00%)	2 / 96 (2.08%)
occurrences (all)	1	1	2
tooth abscess			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
tooth infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
urinary tract infection			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
vaginal infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[10]	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
viral pericarditis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
viral upper respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
vulvovaginal candidiasis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[11]	0 / 6 (0.00%)	0 / 4 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
decreased appetite			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
dehydration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
dyslipidaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	1 / 96 (1.04%)
occurrences (all)	0	0	1
hypercholesterolaemia			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
hyperlipidaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
hypokalaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
obesity			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0
vitamin d deficiency			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	0 / 96 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Escape Arm Week 16 - Maintenance OL - Leb NR/Leb 250 Q2W	Escape Arm Week 24 to 48 - Maintenance OL - Leb 250 Q2W	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	47 / 106 (44.34%)	8 / 18 (44.44%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
cutaneous t-cell lymphoma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
haemangioma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
histiocytic necrotising lymphadenitis			
alternative dictionary used: MedDRA 24.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>penile squamous cell carcinoma</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed^[2]</p> <p>occurrences (all)</p> <p>skin papilloma</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 106 (0.94%)</p> <p>1</p> <p>1 / 63 (1.59%)</p> <p>1</p> <p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 13 (0.00%)</p> <p>0</p> <p>1 / 18 (5.56%)</p> <p>1</p>	
<p>Vascular disorders</p> <p>hypertension</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>peripheral venous disease</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p> <p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 18 (0.00%)</p> <p>0</p>	
<p>General disorders and administration site conditions</p> <p>administration site reaction</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>asthenia</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>chest discomfort</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>chills</p> <p>alternative dictionary used: MedDRA 24.1</p>	<p>0 / 106 (0.00%)</p> <p>0</p> <p>0 / 106 (0.00%)</p> <p>0</p> <p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 18 (0.00%)</p> <p>0</p>	

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
fatigue		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
hyperthermia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
injection site bruising		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
injection site erythema		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
injection site pain		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
injection site pruritus		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
injection site reaction		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
injection site swelling		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	6

non-cardiac chest pain alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
oedema alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
oedema peripheral alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
pyrexia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
swelling face alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
vaccination site pain alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
Immune system disorders food allergy alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
hypersensitivity alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
seasonal allergy alternative dictionary used: MedDRA 24.1			

subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
Reproductive system and breast disorders			
benign prostatic hyperplasia alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[3] occurrences (all)	0 / 63 (0.00%) 0	0 / 13 (0.00%) 0	
cervical dysplasia alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[4] occurrences (all)	0 / 43 (0.00%) 0	0 / 5 (0.00%) 0	
dysmenorrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[5] occurrences (all)	1 / 43 (2.33%) 4	0 / 5 (0.00%) 0	
galactorrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
heavy menstrual bleeding alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[6] occurrences (all)	0 / 43 (0.00%) 0	0 / 5 (0.00%) 0	
vaginal haemorrhage alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[7] occurrences (all)	1 / 43 (2.33%) 1	0 / 5 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
asthma alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	4 / 106 (3.77%) 4	0 / 18 (0.00%) 0	
chronic obstructive pulmonary disease alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
cough		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
dyspnoea		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
epistaxis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
nasal congestion		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
nasal inflammation		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
oropharyngeal pain		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
paranasal sinus inflammation		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
reflux laryngitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0

rhinitis allergic alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	3 / 106 (2.83%) 3	0 / 18 (0.00%) 0	
rhinorrhoea alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
sinus congestion alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
sleep apnoea syndrome alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
Psychiatric disorders anxiety alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
attention deficit hyperactivity disorder alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
delirium alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
depression alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	3 / 106 (2.83%) 3	0 / 18 (0.00%) 0	
insomnia alternative dictionary used:			

MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
persistent depressive disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
sleep disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
stress			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
Investigations			
alanine aminotransferase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
aspartate aminotransferase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
blood creatinine increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
blood lactate dehydrogenase increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
blood phosphorus decreased			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
blood potassium increased alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
blood pressure increased alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
blood urea increased alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
blood uric acid increased alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
eosinophil count increased alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
haemoglobin urine present alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
hepatic enzyme increased alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
lymphocyte count decreased alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0

lymphocyte morphology abnormal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
neutrophil count decreased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
neutrophil count increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
nitrite urine present			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
platelet count increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
protein urine present			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
smear cervix abnormal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[8]	0 / 43 (0.00%)	0 / 5 (0.00%)	
occurrences (all)	0	0	
strongyloides test positive			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
transaminases increased			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
urine bilirubin increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
urine leukocyte esterase positive			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
weight increased			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
Injury, poisoning and procedural complications			
arthropod bite			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
back injury			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
burns second degree			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
contusion			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
epicondylitis			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
head injury		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
ligament sprain		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
meniscus injury		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
muscle strain		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
overdose		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
pelvic fracture		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
post procedural inflammation		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
procedural pain		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0

radius fracture alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
sunburn alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
thermal burn alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
tooth fracture alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
tooth injury alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
upper limb fracture alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
vaccination complication alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
Cardiac disorders angina pectoris alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
palpitations alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
tachycardia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
Nervous system disorders			
carpal tunnel syndrome			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	1 / 18 (5.56%)	
occurrences (all)	0	1	
dizziness			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
dysgeusia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
epilepsy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
essential tremor			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
headache			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	4 / 106 (3.77%)	0 / 18 (0.00%)	
occurrences (all)	7	0	
hypersomnia			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
migraine			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
post herpetic neuralgia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
presyncope			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
radiculopathy			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
sciatica			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
seizure			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
syncope			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
eosinophilia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	3 / 106 (2.83%)	0 / 18 (0.00%)
occurrences (all)	3	0
erythroopenia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
immune thrombocytopenia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
iron deficiency anaemia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
leukopenia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
lymphadenopathy		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
lymphopenia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
neutropenia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0

splenomegaly alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
thrombocytopenia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
Ear and labyrinth disorders deafness unilateral alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
vertigo alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
Eye disorders angle closure glaucoma alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
blepharitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
cataract alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
chalazion alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
conjunctival disorder			

alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
conjunctival hyperaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
conjunctivitis allergic			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	5 / 106 (4.72%)	1 / 18 (5.56%)	
occurrences (all)	5	1	
dry eye			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 106 (1.89%)	0 / 18 (0.00%)	
occurrences (all)	2	0	
eye irritation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	1 / 18 (5.56%)	
occurrences (all)	0	1	
eye pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
eye pruritus			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
eyelid irritation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
eyelid oedema			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
eyelids pruritus		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
glaucomatocyclitic crises		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
keratitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
keratoconus		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
lacrimation increased		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
meibomian gland dysfunction		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
ocular hyperaemia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences (all)	2	0
pupils unequal		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0

vernal keratoconjunctivitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
vision blurred alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
visual impairment alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
Gastrointestinal disorders abdominal discomfort alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
abdominal pain alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
anal haemorrhage alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
constipation alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
dental caries alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
diarrhoea alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
gastric polyps			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
gastrointestinal inflammation			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
mouth ulceration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
nausea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
odynophagia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
toothache			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	1 / 18 (5.56%)	
occurrences (all)	0	1	
vomiting			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
Hepatobiliary disorders			
cholelithiasis			
alternative dictionary used: MedDRA 24.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	
<p>hepatic steatosis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	
<p>non-alcoholic steatohepatitis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	
<p>Skin and subcutaneous tissue disorders</p> <p>acne</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 106 (1.89%)</p> <p>2</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	
<p>alopecia</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	
<p>alopecia areata</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	
<p>dermal cyst</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	
<p>dermatitis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	
<p>dermatitis atopic</p> <p>alternative dictionary used: MedDRA 24.1</p>			

subjects affected / exposed	4 / 106 (3.77%)	1 / 18 (5.56%)
occurrences (all)	5	1
dermatitis contact		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
drug eruption		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
dyshidrotic eczema		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
eczema		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
erythema		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
ingrowing nail		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
milia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
miliaria		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0

papule		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
photosensitivity reaction		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
pruritus		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
rash		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
seborrhoea		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
seborrhoeic dermatitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
skin burning sensation		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
skin lesion inflammation		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
solar dermatitis		
alternative dictionary used: MedDRA 24.1		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>solar lentigo</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>urticaria</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p> <p>0 / 106 (0.00%)</p> <p>0</p> <p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 18 (0.00%)</p> <p>0</p>	
<p>Renal and urinary disorders</p> <p>cystitis noninfective</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>haematuria</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>micturition disorder</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nephrolithiasis</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 106 (0.00%)</p> <p>0</p> <p>0 / 106 (0.00%)</p> <p>0</p> <p>0 / 106 (0.00%)</p> <p>0</p> <p>0 / 106 (0.00%)</p> <p>0</p> <p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 18 (0.00%)</p> <p>0</p>	
<p>Endocrine disorders</p> <p>hyperparathyroidism secondary</p> <p>alternative dictionary used: MedDRA 24.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>hyperthyroidism</p> <p>alternative dictionary used: MedDRA 24.1</p>	<p>0 / 106 (0.00%)</p> <p>0</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
arthritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
back pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
bursitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	1 / 18 (5.56%)	
occurrences (all)	0	1	
growing pains			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
muscle twitching			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
musculoskeletal chest pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
musculoskeletal stiffness			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
myalgia		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
neck pain		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
osteoarthritis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
pain in extremity		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
periarthritis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
rotator cuff syndrome		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
spinal osteoarthritis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
synovial cyst		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0

Infections and infestations abscess limb alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
abscess neck alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
bacterial vaginosis alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[9] occurrences (all)	0 / 43 (0.00%) 0	0 / 5 (0.00%) 0	
bronchitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
covid-19 alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	1 / 18 (5.56%) 1	
cellulitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	0 / 18 (0.00%) 0	
chest wall abscess alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	0 / 18 (0.00%) 0	
conjunctivitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	5 / 106 (4.72%) 6	1 / 18 (5.56%) 1	
conjunctivitis bacterial alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
conjunctivitis viral		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
ear infection		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
ecthyma		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
eczema herpeticum		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
endophthalmitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
folliculitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
fungus skin infection		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	1
furuncle		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0

gastroenteritis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
gastroenteritis viral			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
genital herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	1 / 18 (5.56%)	
occurrences (all)	0	1	
gingivitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
helicobacter infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
herpes dermatitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 106 (1.89%)	0 / 18 (0.00%)	
occurrences (all)	2	0	
herpes simplex			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
herpes zoster			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
impetigo			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
infected cyst		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	1
influenza		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
labyrinthitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
localised infection		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
lower respiratory tract infection		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
myringitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
nasopharyngitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	4 / 106 (3.77%)	0 / 18 (0.00%)
occurrences (all)	5	0
ophthalmic herpes simplex		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0

oral herpes			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
otitis media			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
paronychia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
peritonsillar abscess			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
pertussis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
pharyngitis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
pharyngitis streptococcal			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
pneumonia aspiration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
postoperative wound infection			
alternative dictionary used: MedDRA 24.1			

subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
respiratory tract infection viral		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
secondary syphilis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
sinusitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
skin infection		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
tinea capitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
tinea cruris		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0
tinea versicolour		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0
tonsillitis		
alternative dictionary used: MedDRA 24.1		
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	0

tooth abscess			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 106 (1.89%)	0 / 18 (0.00%)	
occurrences (all)	2	0	
tooth infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	1 / 18 (5.56%)	
occurrences (all)	0	1	
upper respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
urinary tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	1 / 18 (5.56%)	
occurrences (all)	1	1	
vaginal infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[10]	0 / 43 (0.00%)	0 / 5 (0.00%)	
occurrences (all)	0	0	
viral pericarditis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
viral upper respiratory tract infection			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
vulvovaginal candidiasis			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed ^[11]	0 / 43 (0.00%)	0 / 5 (0.00%)	
occurrences (all)	0	0	
Metabolism and nutrition disorders			

decreased appetite			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
dehydration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
dyslipidaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
hypercholesterolaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
hyperlipidaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
hypokalaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	
obesity			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 106 (0.94%)	0 / 18 (0.00%)	
occurrences (all)	1	0	
vitamin d deficiency			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 106 (0.00%)	0 / 18 (0.00%)	
occurrences (all)	0	0	

Notes:

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 October 2019	<ul style="list-style-type: none">• Clarification of primary, co-primary and secondary endpoints to be analyzed for the FDA and EMEA• Updated inclusion criterion 10 for contraceptive use after last dose of study drug (increased from 17 to 18 weeks)• Added inclusion criterion 11 to require male patients to use an effective method of contraception if sexually active with a female of child-bearing potential.• Other minor clarifications and editorial changes.
20 May 2020	<ul style="list-style-type: none">• Added hormone testing to adolescent patients• Removed requirement for TB screening serology at screening visit.• Added PK sample at Week 4• Clarifications on analysis timing, study procedures and protocol wording.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
24 March 2020	Global enrollment hold on new patient screening and enrollment.	28 May 2020

Notes:

Limitations and caveats

None reported